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ew Paradigms of Myocardial
egeneration Post-Infarction
issue Preservation, Cell Environment, and Pluripotent Cell Sources
ames S. Forrester, MD, FACC, Anthony J. White, MD, Satoshi Matsushita, MD,
arun Chakravarty, MD, Raj R. Makkar, MD, FACC
os Angeles, California
eta-analyses of intracoronary autologous bone marrow cell infusion in patients with acute myocardial
nfarction establish the procedure as safe. Nonetheless, the typical small increase in ejection fraction is
f uncertain clinical signiﬁcance, with little if any evidence of myocardial regeneration. In this paper,
e describe 3 new paradigms of myocardial preservation and regeneration that provide reasonable
ope that the goal of myocardial rejuvenation can be achieved. The ﬁrst paradigm is that substantial
reservation of myocardium is possible even during the period of coronary occlusion and immediate
eperfusion, before interventions aimed at myocardial regeneration. The factors that induce myocardial
reservation may also create an environment more receptive to subsequent myocardial regeneration.
he second paradigm is that the local environment may regulate the behavior of cells in the ischemic/
nfarct region. For instance, adult cells may be induced to re-enter the cell cycle and proliferate with
ppropriate environmental modiﬁcation. The ﬁnal paradigm is that autologous cardiac stem cells or
nduced pluripotent stem cells can create new myocytes and myocardium. Taken together, these new
deas, each still to be proven, suggest that the goal of regenerating functioning new myocardium can


















rn 2001, reports that intramyocardial injection of
ematopoietic stem cells induced marked histo-
ogic and functional improvement in the rodent
yocardial infarct model led to worldwide clinical
esearch focused particularly on intracoronary in-
usion of autologous bone-marrow mononuclear
ells (BMCs). The hypothesis that hematopoietic
tem cells can give rise to fully differentiated
ardiomyocytes, however, was subsequently chal-
enged by several laboratories (1) when labeled
ematopoietic stem cells injected directly into isch-
mic murine myocardium did not express cardiac
issue-specific markers and largely disappeared by
0 days. Later meta-analyses of intracoronary au-
rom Cedars-Sinai Medical Center, Division of Cardiology, Los Ange-
es, California.n
anuscript received June 13, 2008; revised manuscript received October 6,
008, accepted October 10, 2008.ologous BMC infusion in clinical acute myocar-
ial infarction (MI) suggested that although the
rocedure induces no increase in late arrhythmias
r rehospitalization, the mean absolute increase in
jection fraction is approximately 4% (2). Random-
zed trials reporting clinical outcomes at 1 year
ave been similarly mixed. In the REPAIR-AMI
Intracoronary Progenitor Cells in Acute Myocar-
ial Infarction) trial, which randomized 204 pa-
ients to intracoronary BMCs or placebo at 3 to 7
ays after reperfusion, the composite end point of
eath, MI, or revascularization was significantly
educed at 12 months (3), but other trials reported
n absence of long-term clinical benefit. Most
nvestigators now feel that BMCs may induce
aracrine growth factor stimulation or physical
caffolding against cardiac dilation but does not
egenerate myocardium (4). Although the mecha-
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2ration are many, they may be categorized as related to the
ells used, the cells’ environment, and barriers created by
issue (Fig. 1). In this paper, we first review the evidence
hat myocardium can regenerate, and then use 3 paradigms
f tissue preservation and regeneration (Fig. 2) to provide a
ramework for clinicians interested in the research develop-
ents that suggest myocardial regeneration in man remains
ossible.
vidence That Myocardium Can Regenerate
yocardial regeneration clearly can occur spontaneously in
onmammalian species. In zebrafish, complete myocardial
egeneration occurs within 2 months of amputation of the
ardiac apex (5). After fibrin seals the wound, cardiomyo-
ytes infiltrate the clot at its leading epicardial edge and
egin proliferating. Bromodeoxyuridine (BrdU) incorpora-
ion, a marker of cell proliferation, peaks at about 14 days.
he advancing edge of proliferating cells then moves pro-
ressively deeper over time, suggesting that regeneration
remains localized to the interface
with the injured area. Regenera-
tion can be eliminated by a mu-
tation in a mitotic checkpoint
kinase (Mps1) that regulates the
cell cycle, leading to scar forma-
tion typical of infarction in
mammals. Collagen deposition,
driven by inflammatory cyto-
kines in mammalian species, is
not seen in the zebrafish.
In mammals, however, spon-
taneous myocardial regeneration
has been documented only in the
RL mouse, colloquially called the scarless mouse because
f its unique capacity to regenerate tissue after injury. In this
utant animal, initially created for the study of immune
eficiency, the histologic response to myocardial injury
esembles the regenerative process seen in zebrafish.
eferovich et al. (6) found that cryogen-induced transmural
ight ventricular infarction in the MRL mouse also heals
ithin 2 months, with restoration of histologically and
unctionally normal myocardium. The regenerating myocar-
ium exhibits a mitotic index of 10% to 20%, compared
ith 1% to 3% for control mice. Hydroxyproline levels, a
arker of new collagen synthesis, are reduced. Although
RL mouse myocardium clearly has the capacity to regen-
rate, studies in our laboratory and others showed that after
xtensive cryoablation and after MI induced by left coronary
rtery ligation, infarct size is no different from that in
onmutant mice, with a transmural infarction surrounded
y collagenous scar. Reviewing these seemingly contradic-







SC  cardiac stem cell
I  myocardial infarction
ISK  reperfusion injury
erine kinase
GF  transforming growth
actoragnitude of the inflammatory response induced by exten- oive cryoablation or coronary occlusion compared with
imited cryoablation may provide an explanation for these
ontradictory results. If this postulate is valid, its potential
linical relevance is that the inflammatory environment at 3
o 7 days after infarction may have influenced the effective-
ess of prior clinical stem cell trials. If so, then acute
reservation of myocardium, an independent goal of ongo-
ng research, may also benefit subsequent therapy directed at
yocardial regeneration at 3 to 6 days after the clinical
vent.
he Paradigm of Myocardial Preservation
uring Ischemia and Reperfusion
hortly after occlusion, apoptosis affects more than 80%,
nd necrosis 20% of the myocytes in the ischemic zone
8). In the first few hours post-occlusion, substantial reduc-
ion of apoptotic cell death is possible. The most promising
pproach to prevention of apoptosis, with concomitant
imitation of post-reperfusion inflammation, can be traced
ack to pre-conditioning studies in which repeated episodes
f transient coronary occlusion before permanent coronary
cclusion resulted in a marked infarct size reduction (9).
or instance, the ratio of infarct size to area at risk was
educed from 48.2% in control animals to 15.1% in rabbits
ubjected to 2 cycles of 5-min ischemia separated by 10 min
eperfusion before 30 min of occlusion and 3 h of reperfu-
ion. Myocardium is also preserved when intermittent
cclusion is implemented after reperfusion (termed post-
onditioning), with the caveat that the procedure is only
ffective when implemented immediately post-reperfusion.
n the same rabbit model, 6 cycles of 10 s of occlusion
eparated by 10 s of reperfusion reduced the ratio of infarct
ize to area at risk to 20.4%. Post-conditioning also has been
emonstrated in humans (10). Stented acute MI patients
ere randomized to either no further intervention or 4
pisodes of 1 min balloon inflation followed by 1 min of
eflation initiated within 1 min of reperfusion. Creatine
inase release fell by 36%, and angiographic blush grade
ncreased by 25% in the post-conditioning group, with no
dverse events. At 6 months the single-photon emission
omputed tomography rest-redistribution index, a measure
f infarct size, was 19.5% in control subjects versus 11.8% in
he post-conditioned group, and at 1 year the post-
onditioned group exhibited a statistically significant 7%
reater left ventricular ejection fraction.
Pre- and post-conditioning can be reproduced by phar-
acologic intervention. The conditioning mechanism in-
olves mediators that induce expression and/or activation of
erine kinases (nicknamed the reperfusion injury serine
inase [RISK] pathway) that act through closure of mito-
hondrial transition pores (11) (Fig. 3). When delivered
efore or soon after coronary occlusion, for instance, aden-
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3ine also is one of the most potent natural inhibitors of
nflammation post-infarct/reperfusion. Recently developed
denosine receptor agonists that are effective in small doses
nd lack adenosine’s undesirable hypotensive or atrioven-
ricular blocking action have this effect. For instance,
nfusion of an adenosine receptor A2A agonist for 30 min
efore and after a 90-min occlusion/reperfusion reduced
nfarct size from 33% to 17% at 48 h in canine MI (12).
A number of clinical trials using pre-conditioning agents
hat are effective in pre-clinical studies, however, have not
esulted in benefit. Most of these trials have 1 of 2 features
hat may explain the difference from the animal laboratory
tudies: the agents were infused much later after the onset of
oronary occlusion and/or were not given before reperfu-
ion. In this respect, 1 trial of adenosine may provide some
nsight. Kloner et al. (13) reported the results of anterior
T-segment elevation MI patients randomized to placebo
ersus adenosine (50 or 70 g/kg/min for 3 h) starting
ithin 15 min of reperfusion. In patients reperfused 3.2 h
fter symptom onset, adenosine significantly reduced both
-month mortality (9.2% vs. 5.2%) and the 6-month com-
osite clinical end point of death, in-hospital congestive
eart failure, or rehospitalization for congestive heart failure
17% vs. 12%). In the larger cohort that included patients
eperfused beyond 3 h, however, no clinical benefit was
een, although infarct size, as in the animal model, was
Figure 1. Barriers to Myocardial Regeneration
Barriers to myocardial regeneration exist at the level of the cell, its environme
cell delivery after infarction is, as yet, unknown. Favoring delayed delivery is th
practical issues of bone marrow cell acquisition and preparation, led to the ch
lead to a more stable local environment, increasingly dense collagen depositio
Figure illustration by Rob Flewell. EF  ejection fraction.educed by about one-half. These laboratory and clinical sata suggest that significant preservation of myocardium
uring coronary occlusion and reperfusion is possible, but
hat the therapy may have to be given early after coronary
cclusion and before or coincident with reperfusion.
A secondary benefit of myocardial preservation is that the
ntervention may create an environment more receptive to
yocardial regeneration therapies. Stem cell engraftment
nd survival is substantially altered by the local cellular
nvironment. Thus, Laflamme et al. (14) found that
hereas 90% of labeled human cardiomyocyte stem cells
ngrafted in uninjured rat hearts, in only 18% of infarcts
ere any human cells detected, and the cells that did engraft
ere found as small clusters (14).
he Paradigm That Local Environment
ay Regulate Tissue Regeneration
he MRL mouse studies suggest that myocytes may
etain the capacity to regenerate depending upon the
ocal environment. The potential importance of a condu-
ive environment is suggested by stem-cell-induced neu-
al regeneration studies in rats with virus-induced hind
imb paralysis (15). To overcome myelin-mediated stem
ell repulsion, Deshpande et al. (15) used adenosine
gonists, then added a neurotrophic factor to attract
ransplanted embryonic stem cell-derived axons toward
he adjacent tissue. In addition to these barriers, the optimal timing of stem
ural ebb of acute inﬂammation over time. This consideration, along with the
f 6 days as the delay period in clinical trials. Although longer delay could
ht create an insuperable barrier to cell migration and to tissue organization.nt in t
e nat
oice o
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4he effect of cellular inhibitors combined with stimulation
f cell migration and proliferation led to axonal growth,
ormation of neuromuscular junctions, and restoration of
ind limb function at 4 months. No axonal growth
ccurred with administration of the embryonic stem cells
lone. The authors concluded that a dual strategy con-
isting of suppression of local inhibitors combined with
timulation of cell proliferation was essential for regen-
rative growth and migration.
Evidence suggesting the existence of 2 potentially com-
eting pathways after injury (i.e., regeneration vs. scarring)
lso comes from embryologic studies. Mammals early in
mbryologic development exhibit scarless healing. For in-
tance, epithelial injury in a fetal rat on day 16 exhibits
carless healing whereas the same injury a few days later
nduces a scar. The transition from scarless healing to scar
ormation coincides with the appearance of the inflamma-
ory response. Thus, one possible explanation for the tran-
ition from scarless embryologic healing seems to be the
ell–environment interaction. For instance, scarless embry-
logic healing is characterized by expression of transforming
rowth factor (TGF) 3, whereas in scarring TGF 1 and
2 isoforms predominate (16). When TGF 3 is applied to
n incisional injury in animals and humans, it markedly
educed and sometimes eliminated incisional scar formation
Figure 2. Mechanisms and Means of Preservation and Regeneration
Three mechanisms that may be used to preserve and regenerate myocardium
(orange circles). Myocardial preservation may be achieved by stimulating the
post-conditioning. Myocardial regeneration may be accomplished by stimulatin
stem cells (CSCs) or induced pluripotent cells. Each mechanism represents a n
is supported by recent animal laboratory research. CDC  cardiosphere-deriven adult skin and vascular tissue. Taken together, these datauggest that scarless healing may be characterized by rever-
ion of the cell environment to the embryologic state and








Salvage kinases (ERK & PI-3K)
Mitochondrial permeability transition pores
Figure 3. Pathways of Cell Preservation and Cell Death
Pathways of cell preservation and cell death during ischemia and reperfu-
sion. Cell death proceeds through reactive oxygen species, expression of
inﬂammatory mediators, activation of pro-apoptotic genes, and opening of
mitochondrial permeability transition pores. Cell survival proceeds through
several mediators including adenosine, which activates the expression of
pro-salvage serine kinases that oppose the effects of the pro-apoptotic
stimuli. The balance between these 2 pathways probably determines cell
survival during ischemia. ERK  extracellular signal-regulated kinase;
n circles), and some of the means by which these effects may be achieved
usion injury salvage kinase pathway, using strategies of pre-conditioning and
lt cardiomyocytes to re-enter the cardiac cycle, or by delivery of cardiac
radigm in myocardial preservation and regeneration and, although unproven,
RISK  reperfusion injury serine kinase.(gree
reperf
g adu
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5To examine this question, we examined the expression of
mbryologic transcription factors in peri-infarct tissue of
ormal mouse hearts. Three factors (Isl1, Mef2c, and
AND1) were up-regulated 2- to 5-fold in infarcted
yocardium, accompanied by as much as an 18-fold in-
rease in their respective proteins at 14 days. Periostin
xpression (vide infra) increased 90-fold. Taken together,
hese data suggest that a response paralleling cardiogenesis
s activated after MI, but that the balance of local factors
avors scar formation, and that therapeutic modification of the
ell environment might tip the balance to favor regeneration.
yocardial regeneration by creating an environment that
nduces adult cells to re-enter the cell cycle. Direct evidence
or the influence of the local environment on myocardial
egeneration comes from studies of growth mediators
nown to be important in both embryologic development
nd wound healing. For instance, p38 mitogen-activated
rotein (MAP) kinase plays a central role in the transition
rom embryologic to adult cell behavior by activating genes
hat inhibit cell division. In cell cultures, Engel et al. (17)
ound that inhibition of p38 MAP kinase induces in a
arked increase in cell dedifferentiation and a 92% increase
n myocyte proliferation. Extending these studies to the
nimal MI model, they found that when a p38 MAP kinase
nhibitor was combined with fibroblast growth factor to
timulate myocyte and endothelial cell proliferation, scar
olume significantly fell (from 42% to 24%) and fractional
hortening significantly improved (from 34% to 53%) at 3
onths post-infarction. Interestingly, p38 MAP kinase
nhibitors and other mediators with similar effects are
ntiapoptotic and anti-inflammatory.
Periostin is an embryonic factor that is reactivated in the
dult after tissue injury. In myocyte cell culture, extracellular
eriostin induced differentiated mononucleated mammalian
ardiomyocytes to re-enter and complete the full mitotic cell
ycle. Interestingly, the action of periostin required the
resence of one of the members of the RISK pathway
phosphoinositol 3-OH kinase) previously identified as
entral to pre- and post-conditioning, suggesting the pos-
ibility that activation of the RISK pathway during preser-
ation might also contribute to subsequent therapy aimed at
egeneration. Extended to the rat infarct model, periostin
esulted in improved ventricular remodeling and myocardial
unction, reduced fibrosis and infarct size, and increased
ngiogenesis, suggesting that it may be possible to induce
xisting adult cardiomyocytes to proliferate, given the ap-
ropriate cellular environment. In summary, the data sug-
est a new concept for myocardial regeneration. Whereas
rior dogma has been that adult cardiac cells are post-
itotic and incapable of regenerating myocardium, these
ata suggest that at the time of infarction, the cells may
nduce either scar or regeneration depending, in part, upon
he cellular environment. The factors thus far identified to
ave the capacity to induce cell dedifferentiation are also wntiapoptotic and some are known mediators of pre-
onditioning, providing a potential link between the strat-
gies of prevention and regeneration.
he Paradigm That Regeneration May Be
nduced by Cardiac Stem Cells (CSCs)
r Induced Pluripotential Cells
n alternative paradigm is that exogenous primitive cells
an be induced to become functioning adult cardiac cells. A
ariety of primitive noncardiac cells and methods of cell
elivery (19–22) reduce apoptosis, increased capillary den-
ity, and improve ejection fraction in infarct models. Since
MCs have produced weak clinical results, alternative cell
ypes are now under investigation. The advantages of cell
ypes other than BMCs are shown in Figure 4.
yocardial preservation using autologous CSCs. In 2002
utopsied female donor hearts transplanted into male recip-
ents were found to have myocytes, coronary arterioles, and
apillaries with a Y chromosome making up 7% to 10% of
he cells. Subsequently, these highly proliferative CSCs
ere identified in normal hearts, typically located in inter-
titial niches of the atria and ventricles (23). Although the
rigin of these cells remains unclear, the niche serves an
natomic compartment in which stem cell self-renewal,
rotection from cell death, and the fate of stem cell
aughters is regulated by integration of intrinsic cell factors
ith the niche microenvironment. This discovery represents
major paradigm shift since the heart was thought to be a
ost-mitotic organ without the capacity to replace itself.
he new paradigm suggests that apoptotic cardiac cells are
lowly replaced by new cells derived from CSC.
Several laboratories have now shown that injection of
reviously isolated and expanded CSCs can partially restore
egional myocardial structure and function in the animal MI
odel. For instance, Dawn et al. (24) delivered CSCs by
ortic root injection in a 90-min occlusion/4-h reperfusion
at MI model. Treated hearts had a smaller left ventricular
hamber volume and a greater wall thickness in the infarct
rea compared with control animals at 5 weeks. The injected
SCs induced myocardial regeneration and decreased in-
arct size by 29%.
reation of sufﬁcient numbers of CSCs to support regeneration.
potential issue for use of autologous CSCs in man,
owever, is the number of cells to be delivered. At least 2
uccessful approaches to generation of high-volume autol-
gous CSCs are now being pursued, with the goal of clinical
esting. Bearzi et al. (25) identified, isolated, and expanded
uman CSCs from surgical myocardial biopsies of 8 pa-
ients, then injected the cells into the infarcted myocardia of
mmunodeficient rodents. The injected cells generated a
himera with human myocytes, coronary resistance arte-
ioles, and capillaries. Areas of myocardial regeneration
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668%), and 14 of 19 treated rats (74%). Human myocardium
omprised 1.3 mm3 in mice and 3.7 mm3 in rats, of which
pproximately 84% were myocytes, and 8% were vascular
tructures. Remarkably, the human tissue was sufficiently
ntegrated that it contributed to the regional and global
unction of the recipient heart. The CSCs were isolated by
ntigenic selection using antibodies against c-kit, the recep-
or for stem cell factor. This requirement for exposure to
enogenic antibodies could pose a hurdle to regulatory
pproval for clinical trials involving c-kit CSCs.
An alternative approach is the use of cardiosphere-
erived cells (CDCs), which do not require use of antibod-
es for selection. Smith et al. (26) cultured cardiac muscle
amples from endomyocardial biopsy specimens. The pri-
Figure 4. Potential Cell Sources for Myocardial Regeneration: Advantages
Among the most important advantages for individual cell types are the capaci
most important potential disadvantages are the need for immunosupression, p
Rob Flewell.ary culture developed multiple spherical clusters termed eardiospheres, which were then plated to yield CDCs.
uman CDCs were cultured from endomyocardial biopsies
n 69 of 70 patients. In vitro studies demonstrated that the
DCs are cardiogenic. Injected into the border zone of
cute MIs in immunodeficient mice, both the percentage of
iable myocardium within the infarct zone and the ejection
raction were greater in the CDC-treated group than in the
broblast-treated control group at 20 days. Myocardial
egeneration was documented histologically as an increase in
he amount of viable tissue within the infarct zone. It is
ossible that this approach to cardiac cell therapy may be
pproved for initial clinical testing within the coming year.
Modification of the local cell environment is likely to be
critical adjunct to stem cell therapy. To test this hypoth-
isadvantages
ifferentiate into all cardiac cell types and an autologous origin. Among the
ial for tumor formation, and difﬁculty of cell acquisition. Figure illustration byand D
ty to d
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7actors that were delivered with human embryonic stem-
ell-derived cardiomyoctes in the rat infarct model. Com-
ared with stem cells alone, the cells of the treated animals
eveloped much larger segments of human myocardium
ithin the infarcted area, and exhibited a 2.5-fold increase
n regional wall thickening (14).
he potential for cardiac regeneration using autologous-
nduced pluripotent cells. In the less immediate future is the
ossibility that autologous pluripotent cells can be derived
rom adult noncardiac tissue. Guan et al. (27) recently
eported the creation of pluripotent stem cells with pheno-
ypic characteristics of embryonic stem cells from adult
ouse testes. These cells are capable of spontaneous differ-
ntiation into cells of all 3 germ layers. With manipulation
f the cell culture environment, the cells were induced to
ifferentiate into functional cardiomyocytes that expressed
ardiac-specific L-type calcium (Ca2) channels and re-
ponded to Ca2 channel-modulating drugs. The cells also
ormed functional gap junctions, and when beating they
xhibited rhythmic Ca2 transients. The beating frequency
as responsive to stimulation with isoproterenol, and sup-
ression by cadmium chloride abolished spontaneous elec-
rical activity. When transplanted into a normal mouse
earts, the cells were able to proliferate and differentiate.
atient-specific autologous cardiomyocytes derived from
esticular biopsy could circumvent the ethical and immuno-
ogical problems associated with human embryonic stem
ells.
Two laboratories have shown that pluripotent human
ells similar to embryonic stem cells also can be created from
ermal fibroblasts by retroviral introduction of 4 transgenes.
wo of the transgenes are the same in both laboratories
Oct3/4, Sox2) and 2 are different (28,29). These studies
uggest that transcription factor-induced nuclear repro-
ramming can lead to the reversion of somatic cells to an
mbryonic cell-like state. Placed in an appropriate environ-
ent (activin A and bone morphogenic protein), these cells
an develop into beating cardiomyocytes. The requirement
or genetic modification may dampen the prospect for rapid
egulatory approval of ethical trials since at least some of
hese cell lines have the capacity to induce teratoma forma-
ion. As a consequence, other lines of research are focusing
n methods of cell selection that allow creation of pluripo-
ent cells that lack this capacity.
pproaches to improving stem cell engraftment and persis-
ence. Independent of the cell source is an additional
roblem of inadequate cell engraftment, persistence, and
otentially inhomogeneous cell distribution. One potential
olution, at least during surgery, is the use of a synthetic
atrix (30). Both gelfoam and biologic matrices are being
ested. For instance, in one such application, human mes-
nchymal stem cells were embedded into a tissue-
ngineered cardiac patch containing a rat tail type I collagen
atrix, and attached with fibrin sealant to the epicardial
1urface of immunocompromised rat anterior MI. When the
atches were applied after 4 days of culture, 90% of cells
ere viable. At 1 week, 23% of mesenchymal cells had
ngrafted. At 4 weeks, anterior wall thickness increased and
ractional shortening increased by 30%. Patches alone in-
uced no improvement. Nonetheless, in the treated animals,
esenchymal cells were not detectable at 4 weeks, suggest-
ng that although improvement did not require long-term
ell engraftment, persistence of cells in host tissue may
equire more than purely mechanical solutions.
onclusions
linical trials of intracoronary delivery of autologous BMC
nfusion in acute MI have established safety and feasibility
ith only a modest effect on cardiac perfusion and function,
nd with no evidence for creation of new myocardium.
hese equivocal results have been paralleled by 3 new
till-to-be-proven paradigms that suggest that with perse-
erance the goal of preserving and then regenerating func-
ioning new myocardium can still be achieved in man.
eprint requests and correspondence: Dr. James S. Forrester,
urns and Allen Professor, Division of Cardiology, Cedars-Sinai
edical Center, 8700 Beverly Boulevard, Los Angeles, California
0048. E-mail: forrester@cshs.org.
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